Aila Biotech

Aila Biotech is a Cambridge-based biotechnology company developing a patented gene delivery platform designed to produce immune-regulating biologics locally at the site of disease. The technology utilizes a dose-responsive small molecule switch, which allows for precise temporal and spatial control over biologic expression within the brain. This targeted approach is intended to overcome the blood-brain barrier and avoid peripheral off-target toxicities, distinguishing it from systemic therapeutic delivery methods. The company focuses on neuroinflammatory conditions, with pre-clinical research demonstrating the efficacy of its platform in mitigating pathology in animal models of traumatic brain injury, multiple sclerosis, and age-associated cognitive decline.

By enabling localized therapy, Aila Biotech aims to transform the clinical treatment of neuroinflammatory diseases and reduce the cognitive loss associated with these conditions. The company’s approach is supported by an experienced team of neuroimmunology and biotech experts, and it has successfully engaged with the Cambridge innovation ecosystem, including the Accelerate@Babraham programme. Currently, the company is advancing its flagship product toward first-in-human clinical trials while continuing to develop other high-value biologics using its proprietary delivery system. This work is critical for patients suffering from chronic neuroinflammatory conditions where traditional systemic treatments are often limited by toxicity or poor penetration of the central nervous system.